Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Citicoline in stroke and TBI clinical trials

Nature Reviews Neurology volume 9, page 173 (2013)Cite this article

Subjects

Access through your institution
Buy or subscribe

The results of recent citicoline trials by Dávalos et al.1 and Zafonte et al.2 showed that citicoline is not efficacious in treating stroke and TBI, respectively, a view that has been echoed by others,3,4 including a recent News & Views article in this journal (Stroke: Treatment for acute stroke—the end of the citicoline saga. Nat. Rev. Neurol. 8, 484–485; 2012).5 Studies in rodent models of stroke, however, have indicated that bioavailability of this drug may be an issue that has been repeatedly overlooked in the clinical trials, making it premature to conclude that citicoline is ineffective. Our and others' research with animal models strongly suggests that if a liposome formulation had been used, the reported results from the clinical trial would have been different.6,7,8,9

Route of administration, bioavailability and metabolism of citicoline are vital factors in stroke and TBI clinical trials. On the basis of absorption and excretion, bioavailability of citicoline is believed to be the same between oral and intravenous routes. Animal studies have shown, however, that brain uptake of citicoline is greater with the intravenous route than with the oral route.7 Citicoline metabolism in humans differs from that in rodents: in rodents, citicoline administration increases blood plasma levels of cytidine and choline, while in humans blood plasma levels of uridine but not cytidine are increased due to cytidine deaminase in the gastrointestinal tract and liver.10 In both humans and rodents, citicoline is metabolized to choline and cytidine triphosphate (CTP) by the liver; after passing through a compromised blood–brain barrier (BBB) these two components need to be reassembled by rate-limiting CTP:phosphocholine cytidylyltransferase (CCT), which is downregulated after stroke. Downregulation of CCT and upregulation of phospholipases result in significant phosphatidylcholine loss,11,12 and the therapeutic action of citicoline is thought to be due to stimulation of phosphatidylcholine synthesis.13

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Dávalos, A. et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet 380, 349–357 (2012).

    Article  Google Scholar 

  2. Zafonte, R. D. et al. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT). JAMA 308, 1993–2000 (2012).

    Article  CAS  Google Scholar 

  3. Bustamante, A. et al. Citicoline in pre-clinical animal models of stroke: a meta-analysis shows the optimal neuroprotective profile and the missing steps for jumping into a stroke clinical trial. J. Neurochem. 123, 217–225 (2012).

    Article  CAS  Google Scholar 

  4. Ruff, R. L. & Riechers, R. G. Effective treatment of traumatic brain injury: learning from experience. JAMA 308, 2032–2033 (2012).

    Article  CAS  Google Scholar 

  5. Clark, W. M. & Clark, T. D. Stroke: Treatment for acute stroke—the end of the citicoline saga. Nat. Rev. Neurol. 8, 484–485 (2012).

    Article  CAS  Google Scholar 

  6. Adibhatla, R. M., Hatcher, J. F. & Tureyen, K. CDP-choline liposomes provide significant reduction in infarction over free CDP-choline in stroke. Brain Res. 1058, 193–197 (2005).

    Article  Google Scholar 

  7. Fresta, M., Wehrli, E. & Puglisi, G. Enhanced therapeutic effect of cytidine-5′-diphosphate choline when associated with GM1 containing small liposomes as demonstrated in a rat ischemia model. Pharm. Res. 12, 1769–1774 (1995).

    Article  CAS  Google Scholar 

  8. Ghosh, S., Das, N., Mandal, A. K., Dungdung, S. R. & Sarkar, S. Mannosylated liposomal cytidine 5′ diphosphocholine prevent age related global moderate cerebral ischemia reperfusion induced mitochondrial cytochrome c release in aged rat brain. Neuroscience 171, 1287–1289 (2010).

    Article  CAS  Google Scholar 

  9. Ramos-Cabrer, P., Agulla, J., Argibay, B., Perez-Mato, M. & Castillo, J. Serial MRI study of the enhanced therapeutic effects of liposome-encapsulated citicoline in cerebral ischemia. Int. J. Pharm. 205, 228–233 (2011).

    Article  Google Scholar 

  10. Wurtman, R. J., Regan, M., Ulus, I. & Yu, L. Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochemical Pharmacology 60, 989–992 (2000).

    Article  CAS  Google Scholar 

  11. Adibhatla, R. M. & Hatcher, J. F. Role of lipids in brain injury and diseases. Future Lipidol. 2, 403–422 (2007).

    Article  CAS  Google Scholar 

  12. Adibhatla, R. M. & Hatcher, J. F. Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid. Redox Signal. 12, 125–169 (2010).

    Article  CAS  Google Scholar 

  13. Adibhatla, R. M. & Hatcher, J. F. Cytidine 5′-diphosphocholine (CDP-choline) in stroke and other CNS disorders. Neurochem. Res. 30, 15–23 (2005).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurological Surgery, Room H4-330, Clinical Sciences Center, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA. adibhatl@neurosurg.wisc.edu,

    Rao Muralikrishna Adibhatla

Authors
  1. Rao Muralikrishna Adibhatla
    View author publications

    Search author on:PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adibhatla, R. Citicoline in stroke and TBI clinical trials. Nat Rev Neurol 9, 173 (2013). https://doi.org/10.1038/nrneurol.2012.166-c1

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrneurol.2012.166-c1

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing